Board of Directors
Doug Levinson, PhD
Doug Levinson has created and led numerous successful companies in the life sciences. Prior to Cytrellis Doug was a Partner at Flagship Ventures where he co-founded and served as CEO of T2 Biosystems and Seventh Sense Biosystems. Doug was a member of the founding team of TransForm Pharmaceuticals and served as a member of the Management Team from the company’s initial founding through its acquisition by J&J in 2006. At TransForm, He served as Vice President of Emerging Science and Technology where he led the design, development and implementation of TransForm’s basic technology platforms and business model. Prior to TransForm, Doug was with Millennium Pharmaceuticals, which he joined as a founding scientific team member. At Millennium for seven years, he was responsible for establishing the company’s early scientific program in Immunology/Inflammation. Before joining Millennium, he was with Creative Biomolecules where he was responsible for the generation of synthetic single-chain antibody molecules. Doug holds a Ph.D. in Genetics from Harvard University and a B.S. cum laude in Molecular Biology from the University of Massachusetts. He has authored numerous patents in the field of high throughput platform technologies and molecular genetics and has published extensively in scientific journals.
Chief Financial Officer
Diane Marcou is an independent financial consultant working with early stage companies where she has applied her strategic planning and leadership capabilities to identify, implement and improve business systems and support growth. Diane has provided financial and strategic advisory services to a number of venture-backed technology and life sciences companies, including Fractyl Laboratories Inc., T2 Biosystems, TARIS Biomedical, ByAllAccounts, Inc., Ivenix and Topera Medical. For more than 20 years working across private and public sector organizations, she has consistently built effective teams, strengthened relationships with investors, partners, customers and employees, and secured funding and negotiated critical business agreements. Prior to working as an independent financial consultant, she was Chief Financial Officer and VP of Finance and Administration for Incentive Systems (dba Centive), a privately held venture-funded software company, and Chief Financial Officer at Workgroup Technology, a publicly traded software company with domestic and international operations. Diane earned her CPA at PricewaterhouseCoopers, formerly Coopers & Lybrand and a BS in Business Administration from Boston College.
Alec Ginggen, PhD
Alec Ginggen has a strong track record of medical device development from early stage research to product launch. Alec started his career with Codman, a Johnson&Johnson company. Responsible for developing innovative technologies for the corporation, he played a critical role in the implementation of a center of excellence for smart implantable devices. He brought complex implantable devices to market involving a variety of technologies that includes drug delivery, biophysical parameters sensing, microsystems, trans-cutaneous wireless communication, implantable electronics and software. He then joined the J&J Corporate Office of Science and Technology where he led an internal venture program aiming at transforming the treatment of neurodegenerative diseases through early research. In this role, he was also responsible for identifying transformational technologies of interest for the corporation. Alec completed his Ph.D. in Physics at the Swiss Federal Institute of Technology in Lausanne, where he also holds an M.S. Degree in Physics. He holds more than 50 patent and patent application families
Karen Cronholm, M.B.A.
Director Strategic Marketing
Karen Cronholm has more than 18 years’ experience in the life sciences and medical device industry. Most recently, Karen was Head of Field Marketing for the Lab Solutions business at EMD Millipore. Prior to her assignment at EMD Millipore, she was a Senior Product Manager at Cynosure, Inc. While at Cynosure, Karen managed the body contouring franchise, directed marketing and product management of several product lines and led development and launch of Cellulaze ™ for treatment of cellulite. Through her 12 year tenure at EMD Millipore she held various roles such as marketing manager and research and development scientist. She began her career in the biotech industry working with, TransKaryotic Therapies. Karen has a B.S. in Microbiology from the University of New Hampshire and earned an M.B.A. with honors from Northeastern University.
Rox Anderson, MD
Founder, Medical / Technology Advisor
Dr. Anderson graduated from MIT, and then received his MD degree magna cum laude from the joint MIT-Harvard medical program, Health Sciences and Technology. After completing his dermatology residency and an NIH research fellowship at Harvard, he joined the faculty where he is now Harvard Medical School Professor in dermatology, Director of the Wellman Center for Photomedicine; and adjunct Professor of Health Sciences and Technology at MIT. Dr. Anderson conceived and developed many of the non-scarring laser treatments now widely used in medical care. These include treatments for birthmarks, microvascular and pigmented lesions, tattoo and permanent hair removal. He has also contributed to treatment for vocal cords, kidney stones, glaucoma, heart disease, photodynamic therapy for cancer and acne, optical diagnostics and non-invasive fat removal. He co-invented fractional laser treatment, which is useful for improving burn scars, and recently developed a new strategy for epidermal grafting of wounds. His research has advanced the basic knowledge of human skin photobiology, drug photosensitization mechanisms, tissue optics, and laser-tissue interactions. In addition to research at the Wellman Center, Dr. Anderson practices dermatology at Massachusetts General Hospital and teaches at Harvard and MIT and serves on many clinical advisory boards and industry committees. Dr. Anderson has been awarded over 60 national and international patents, and has co-authored over 250 scientific books and papers.
William G. Austen, Jr. MD
Founder, Medical / Technology Advisor
Dr. Austen is the Chief of the Division of Plastic & Reconstructive Surgery and Chief of the Division of Burn Surgery at the Massachusetts General Hospital, Harvard Medical School. He received his undergraduate degree at Princeton followed by his medical degree at Harvard Medical School. He trained in General Surgery and Plastic Surgery at Harvard Medical School followed by a Fellowship in Craniofacial Surgery at the Royal Children’s Hospital in Melbourne, Australia. Dr. Austen’s laboratory focuses on translational research in the field of plastic and reconstructive surgery, with an emphasis on moving novel concepts in the field from the bench top to the bedside. Dr. Austen is a member of numerous societies including the Society of University Surgeons, the American College of Surgeons, the American Association of Plastic Surgeons, and the American Society of Plastic Surgeons. He has won numerous awards including the Best Paper of the Year in Plastic s& Reconstructive Surgery 2015 and Teacher of the Year in Plastic Surgery at Harvard Medical School.
Keith L. Crandell
Keith Crandell has been the Director of Arch Ventures since February 2007. Since 1994 Keith has served as a managing director of Arch Venture Partners, a venture capital firm focused on early- stage technology companies. He is a director of nine private companies and he also serves as a director of the Illinois Venture Capital Association. Keith holds a B.S. degree in chemistry and mathematics from St. Lawrence University, an M.S. degree in chemistry from the University of Texas at Arlington and an M.B.A. from the University of Chicago. Keith has extensive knowledge of the semiconductor industry and in-depth expertise in finance and investment strategy.
Frederick Beddingfield III, M.D., Ph.D.
Dr. Beddingfield is the Chief Medical Officer at Kythera Biopharmaceuticals, Inc. He is an executive officer of the company, and leads global drug development including clinical development, regulatory affairs, pharmacovigilance, and research compliance, as well as medical affairs. He led a team responsible for the US and Canadian KYBELLA® approvals, which included a 17-0 positive FDA advisory committee vote. The US KYBELLA® approval was followed closely by a $2.1B acquisition of Kythera by Allergan. Previously, he was Vice President and Global Therapeutic Area Head, Dermatology and Aesthetics at Allergan, Inc. where he worked from 2003 until 2013. Dr. Beddingfield is a board certified dermatologist with fellowship training in aesthetic, procedural dermatology and Mohs mirocgraphic surgery and has led the global clinical development programs for premiere products in the dermatology and aesthetics industry, including Allergan’s BOTOX® Cosmetic, JUVEDERM® and LATISSE®, all ground-breaking and market-leading aesthetic treatments in their respective categories. He has led 4 drugs and devices through positive FDA Advisory Committees. He is on the board of Advancing Innovation in Dermatology, sponsor of the Dermatology Summit and Dermatology Entrepreneurship Conferences and is a board member of Sienna Labs, Inc. Dr. Beddingfield earned an M.D. with Honors from the University of North Carolina, a Ph.D. in Policy Analysis from RAND Graduate School of Policy Studies and a B.A. in Psychology from North Carolina State University. He is on the faculty of the UCLA School of Medicine where he sees patients and teaches.
John McDonough is President and Chief Executive Officer of T2 Biosystems and has been a member of T2 Biosystem’s Board of Directors since November 2007. From 2003 to 2007, John held various positions at Cytyc Corporation, a company engaged in the design, development, manufacturing and marketing of clinical products that focus on women’s health, and ultimately served as President at Cytyc Development Corporation. John had the responsibility of designing and executing Cytyc Corporation’s growth strategy for expanding the company from a single product company with revenue of approximately $300 million to a diverse women’s health company with revenue of approximately $750 million. He led the efforts that resulted in Cytyc’s acquisition by Hologic, Inc. in October, 2007, for over $6 billion. He has served in senior executive management and CEO roles in several private and public companies. He is currently also a member of the Board of Directors at Solace Therapeutics. Mr McDonough earned his B.S.B.A. from Stonehill College.
Amit Munshi is currently President and Chief Executive Officer at Epirus. Amit is a former CEO of Percivia LLC and also was a co-founder, and the chief business officer at Kythera Biopharmaceuticals. Previously, he has held leadership positions at Amgen, including General Manager of European Nephrology. Amit has more than 24 years of pharmaceutical and biotechnology experience both in the United States and internationally, including general management, product development, licensing, and business development.